Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2017 Sep;15(9):1091-1102. doi: 10.6004/jnccn.2017.0147.

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.

Author information

1
From The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Moffitt Cancer Center; Massachusetts General Hospital Cancer Center; UC San Diego Moores Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; City of Hope Comprehensive Cancer Center; Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; University of Alabama at Birmingham Comprehensive Cancer Center; University of Michigan Comprehensive Cancer Center; University of Washington/Seattle Cancer Care Alliance; Fred & Pamela Buffett Cancer Center; Stanford Comprehensive Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Vanderbilt-Ingram Cancer Center; The University of Texas MD Anderson Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Yale Cancer Center/Smilow Cancer Hospital; Mayo Clinic Cancer Center; University of Colorado Cancer Center; University of Wisconsin Carbone Cancer Center; Memorial Sloan Kettering Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Roswell Park Cancer Institute; and National Comprehensive Cancer Network.

Abstract

The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, the management of relapsed or refractory (R/R) ALL remains challenging and prognosis is poor. The NCCN Guidelines for ALL provide recommendations on standard treatment approaches based on current evidence. These NCCN Guidelines Insights summarize treatment recommendations for R/R ALL and highlight important updates, and provide a summary of the panel's discussion and underlying data supporting the most recent recommendations for R/R ALL management.

PMID:
28874594
DOI:
10.6004/jnccn.2017.0147
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center